Hanna Amir, Connelly Kim A, Josse Robert G, McIntyre Roger S
a 1 Department of Medicine, University of Toronto, Toronto, ON, Canada.
b 2 Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, ON, Canada.
Expert Rev Endocrinol Metab. 2015 Jan;10(1):101-114. doi: 10.1586/17446651.2015.972370. Epub 2014 Oct 21.
The incretin therapies, glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors, have been developed to lower blood glucose levels in patients with Type 2 diabetes. However, in addition to being a treatment strategy to improve metabolic control, incretin therapies have shown effects independent of glycemic control, including the potential to positively impact cardiovascular events, cognitive deficits and bone mineral density. This paper outlines the non-glycemic effects of incretin therapies on cardiovascular disease, cognitive function and bone health.
肠促胰岛素疗法，即胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂，已被开发用于降低2型糖尿病患者的血糖水平。然而，除了作为改善代谢控制的治疗策略外，肠促胰岛素疗法还显示出独立于血糖控制的作用，包括对心血管事件、认知缺陷和骨矿物质密度产生积极影响的潜力。本文概述了肠促胰岛素疗法对心血管疾病、认知功能和骨骼健康的非血糖作用。
